1613108-46-5

Basic information

• Product Name: N-3-chlorophenyl-N'-(6-ethylsulfonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea
• Synonyms: N-3-chlorophenyl-N'-(6-ethylsulfonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea
• CAS NO: 1613108-46-5
• Molecular Weight: 437.947
• Mol File: 1613108-46-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-3-chlorophenyl-N'-(6-ethylsulfonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: N-3-chlorophenyl-N'-(6-ethylsulfonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea(1613108-46-5)
• EPA Substance Registry System: N-3-chlorophenyl-N'-(6-ethylsulfonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea(1613108-46-5)

Safety Data

• Hazardous Substances Data: 1613108-46-5(Hazardous Substances Data)

Upstream product

• 1613108-48-7 3,4-dihydro-2,2-dimethyl-6-ethylsulfonylamino-2H-1-benzopyran-4-hydroxyimine 
• 1613108-30-7 3,4-dihydro-2,2-dimethyl-6-ethylsulfonylamino-2H-1-benzopyran-4-one 
• 186774-62-9 6-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-one 
• 186774-61-8 N-(2,2-dimethyl-4-oxo-3,4-dihydro-2H-1-benzopyran-6-yl)acetamide 
• 7298-67-1 5-acetamido-2-hydroxyacetophenone 
• 104-94-9 4-methoxy-aniline 
• 51-66-1 4-methoxyacetanilide 
• 1613108-50-1 4-amino-3,4-dihydro-2,2-dimethyl-6-ethylsulfonylamino-2H-1-benzopyran 
• 2909-38-8 m-chlorophenyl isocyanate 

Relevant articles and documents

Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: From potassium channel openers to calcium entry blockers?

The present study described the synthesis of original R/S-6- alkylsulfonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans bearing a 3- or 4-substituted phenylthiourea or phenylurea moiety at the 4-position. Their biological effects were evaluated both on insulin-secreting and smooth muscle cells and were compared to those of reference KATP channel activators such as (±)-cromakalim, diazoxide and previously synthesized cromakalim analogues. The study aimed at exploring the influence of the introduction of an alkylsulfonylamino substituent at the 6-position of 2,2-dimethylchromans in order to improve biological activity, tissue selectivity but also hydrophilicity of dihydrobenzopyran derivatives. Several compounds were found to be equipotent or even more potent than (±)-cromakalim and diazoxide at inhibiting the insulin releasing process. Most of the newly synthesized and more hydrophilic dihydrobenzopyrans also exhibited a marked vasorelaxant activity although they were less potent than (±)-cromakalim. Additional pharmacological and radioisotopic investigations suggested that R/S-N-3-chlorophenyl-N-(3,4-dihydro- 6-methylsulfonylamino-2,2-dimethyl-2H-1-benzopyran-4-yl)thiourea (21) did not act as a potassium channel opener but rather as a Ca2+ entry blocker.